Updates to the Formulary - November 2026
A summary of recent updates to the formulary
Newly approved formulary medicines
| Medicine | Indication | Formulary Flag |
|
Deuruxolitinib (Leqselvi) |
Treatment of adult patients with severe alopecia areata. | Specialist Use Only |
|
Seladelpar (Livdelzi) |
For the treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. | Specialist Recommendation |
Details of all recent Formulary Committee decisions can be found on the Formulary Decisions page of the website.
Amendments to the formulary
| Condition/Pathway | Update |
Gastro-oesophageal reflux disease (GORD)
|
‘Co-magaldrox 195mg/220mg/5ml oral suspension sugar free' has been removed from formulary due to being discontinued. |
|
We have removed unlicenced sodium chloride 7% nebuliser liquid preparations from two pathways, as these were included in error. Other strengths and formulations of sodium chloride remain on these pathways. |
|
Removal of budesonide enemas (‘Budenofalk 2mg/application foam enema’ and ‘Entocort 2mg/100ml enema’) from the acute exacerbation of Crohn's disease pathway, as topical products are not considered standard practice for this indication. |
| Gender dysphoria or incongruence | A link to the National Gender Identity Clinical Network for Scotland website was removed as the website is currently under review and the specific guidance we linked to from the formulary is not available at present. |